Advanced Prodrug Strategies in Nucleoside and Non-Nucleoside Antiviral Agents: A Review of the Recent Five Years

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2017 Oct 17

PMID 29035325

Citations 27

Authors

Hanadi Sinokrot

Tasneem Smerat

Anas Najjar

Rafik Karaman

Affiliations

Soon will be listed here.

Abstract

: Poor pharmacokinetic profiles and resistance are the main two drawbacks from which currently used antiviral agents suffer, thus make them excellent targets for research, especially in the presence of viral pandemics such as HIV and hepatitis C. : The strategies employed in the studies covered in this review were sorted by the type of drug synthesized into ester prodrugs, targeted delivery prodrugs, macromolecular prodrugs, other nucleoside conjugates, and non-nucleoside drugs. : Utilizing the ester prodrug approach a novel isopropyl ester prodrug was found to be potent HIV integrase inhibitor. Further, employing the targeted delivery prodrug zanamivir and valine ester prodrug was made and shown a sole delivery of zanamivir. Additionally, VivaGel, a dendrimer macromolecular prodrug, was found to be very efficient and is now undergoing clinical trials. : Of all the strategies employed (ester, targeted delivery, macromolecular, protides and nucleoside analogues, and non-nucleoside analogues prodrugs), the most promising are nucleoside analogues and macromolecular prodrugs. The macromolecular prodrug VivaGel works by two mechanisms: envelope mediated and receptor mediated disruption. Nucleotide analogues have witnessed productive era in the recent past few years. The era of non-interferon based treatment of hepatitis (through direct inhibitors of NS5A) has dawned.

Citing Articles

Nucleoside Analogues for Chagas Disease and Leishmaniasis Therapy: Current Status and Future Perspectives.

Nwoke E, Lowe S, Aldabbagh F, Kalesh K, Kadri H Molecules. 2024; 29(22).

PMID: 39598623 PMC: 11596272. DOI: 10.3390/molecules29225234.

Synthesis and Biological Evaluation of 20(S)-Substituted FL118 Conjugates as Novel Antitumor Agents.

Lai J, Wang M, Hu W, Yue H, Yu E, Zhang X J Mol Struct. 2024; 1268.

PMID: 39545022 PMC: 11563187. DOI: 10.1016/j.molstruc.2022.133661.

Development of 3'-Deoxy-3',4'-didehydro-nucleoside Prodrug Inhibitors of West Nile and Zika Viruses.

Kennelly S, Sawyer J, Payne A, Ciota A, Harki D ACS Med Chem Lett. 2024; 15(8):1334-1339.

PMID: 39140046 PMC: 11318099. DOI: 10.1021/acsmedchemlett.4c00225.

Non-Covalent Inhibitors of SARS-CoV-2 Papain-Like Protease (PLpro): In Vitro and In Vivo Antiviral Activity.

Velma G, Shen Z, Holberg C, Fu J, Soleymani F, Cooper L J Med Chem. 2024; 67(16):13681-13702.

PMID: 39102360 PMC: 11345844. DOI: 10.1021/acs.jmedchem.4c00378.

Chitosan/Alginate-Based Nanoparticles for Antibacterial Agents Delivery.

Wathoni N, Herdiana Y, Suhandi C, Mohammed A, El-Rayyes A, Narsa A Int J Nanomedicine. 2024; 19:5021-5044.

PMID: 38832335 PMC: 11146614. DOI: 10.2147/IJN.S469572.

References

Kumar P, Lakshmi Y, C B, Golla K, Kondapi A . Improved Safety, Bioavailability and Pharmacokinetics of Zidovudine through Lactoferrin Nanoparticles during Oral Administration in Rats. PLoS One. 2015; 10(10):e0140399. PMC: 4604150. DOI: 10.1371/journal.pone.0140399. View

Levy G, Adamson G, James Phillips M, Scrocchi L, Fung L, Biessels P . Targeted delivery of ribavirin improves outcome of murine viral fulminant hepatitis via enhanced anti-viral activity. Hepatology. 2006; 43(3):581-91. PMC: 7165489. DOI: 10.1002/hep.21072. View

Jordheim L, Durantel D, Zoulim F, Dumontet C . Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov. 2013; 12(6):447-64. DOI: 10.1038/nrd4010. View

Galdiero S, Falanga A, Vitiello M, Cantisani M, Marra V, Galdiero M . Silver nanoparticles as potential antiviral agents. Molecules. 2011; 16(10):8894-918. PMC: 6264685. DOI: 10.3390/molecules16108894. View

McGuigan C, Madela K, Aljarah M, Gilles A, Brancale A, Zonta N . Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus. Bioorg Med Chem Lett. 2010; 20(16):4850-4. DOI: 10.1016/j.bmcl.2010.06.094. View

Nicolas J, Mura S, Brambilla D, Mackiewicz N, Couvreur P . Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery. Chem Soc Rev. 2012; 42(3):1147-235. DOI: 10.1039/c2cs35265f. View

Varma M, Ambler C, Ullah M, Rotter C, Sun H, Litchfield J . Targeting intestinal transporters for optimizing oral drug absorption. Curr Drug Metab. 2010; 11(9):730-42. DOI: 10.2174/138920010794328850. View

Gupta D, Varghese Gupta S, Dahan A, Tsume Y, Hilfinger J, Lee K . Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue. Mol Pharm. 2012; 10(2):512-22. PMC: 3572763. DOI: 10.1021/mp300564v. View

Cho A, Zhang L, Xu J, Lee R, Butler T, Metobo S . Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients. J Med Chem. 2013; 57(5):1812-25. DOI: 10.1021/jm400201a. View

10.

Sofia M, Chang W, Furman P, Mosley R, Ross B . Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase. J Med Chem. 2011; 55(6):2481-531. DOI: 10.1021/jm201384j. View

11.

Ruiz-Sanchis P, Wohl B, Smith A, Zuwala K, Melchjorsen J, Tolstrup M . Highly active macromolecular prodrugs inhibit expression of the hepatitis C virus genome in the host cells. Adv Healthc Mater. 2014; 4(1):65-8. DOI: 10.1002/adhm.201400307. View

12.

Varghese Gupta S, Gupta D, Sun J, Dahan A, Tsume Y, Hilfinger J . Enhancing the intestinal membrane permeability of zanamivir: a carrier mediated prodrug approach. Mol Pharm. 2011; 8(6):2358-67. PMC: 3304100. DOI: 10.1021/mp200291x. View

13.

Andrei G, Snoeck R . Emerging drugs for varicella-zoster virus infections. Expert Opin Emerg Drugs. 2011; 16(3):507-35. DOI: 10.1517/14728214.2011.591786. View

14.

Wang K, Shun-Shin M, Gill P, Perera R, Harnden A . Neuraminidase inhibitors for preventing and treating influenza in children (published trials only). Cochrane Database Syst Rev. 2012; (4):CD002744. PMC: 6599832. DOI: 10.1002/14651858.CD002744.pub4. View

15.

Regueiro-Ren A, Xue Q, Swidorski J, Gong Y, Mathew M, Parker D . Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 12. Structure-activity relationships associated with 4-fluoro-6-azaindole derivatives leading to the identification of.... J Med Chem. 2013; 56(4):1656-69. DOI: 10.1021/jm3016377. View

16.

Nazemi A, Haeryfar S, Gillies E . Multifunctional dendritic sialopolymersomes as potential antiviral agents: their lectin binding and drug release properties. Langmuir. 2013; 29(21):6420-8. DOI: 10.1021/la400890f. View

17.

Cavalli R, Donalisio M, Bisazza A, Civra A, Ranucci E, Ferruti P . Enhanced antiviral activity of acyclovir loaded into nanoparticles. Methods Enzymol. 2012; 509:1-19. DOI: 10.1016/B978-0-12-391858-1.00001-0. View

18.

Haldar J, Alvarez de Cienfuegos L, Tumpey T, Gubareva L, Chen J, Klibanov A . Bifunctional polymeric inhibitors of human influenza A viruses. Pharm Res. 2009; 27(2):259-63. PMC: 2847411. DOI: 10.1007/s11095-009-0013-1. View

19.

Smith A, Zuwala K, Kryger M, Wohl B, Guerrero-Sanchez C, Tolstrup M . Macromolecular prodrugs of ribavirin: towards a treatment for co-infection with HIV and HCV. Chem Sci. 2017; 6(1):264-269. PMC: 5435870. DOI: 10.1039/c4sc02754j. View

20.

Wohl B, Smith A, Kryger M, Zelikin A . Narrow therapeutic window of ribavirin as an inhibitor of nitric oxide synthesis is broadened by macromolecular prodrugs. Biomacromolecules. 2013; 14(11):3916-26. DOI: 10.1021/bm401048s. View